Showing results (121-130 of 205) with videos related to

Sort By:
Pageof 21
Blood|July 3, 2013
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylationJing Lu, Tatiana Zavorotinskaya, Yumin Dai, et al.
Journal of the American Medical Informatics Association : JAMIA|March 3, 2007
Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicitiesEthan Basch, David Artz, Alexia Iasonos, et al.
Plos One|May 26, 2018
Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapyOlga Ksionda, Marsilius Mues, Anica M Wandler, et al.
Molecular Cancer Therapeutics|August 28, 2020
Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEKDaniela Pucciarelli, Steven P Angus, Benjamin Huang, et al.
The Western Journal of Emergency Medicine|April 29, 2026
Reducing Emergency Diagnostic Uncertainty with TRACE: Triage and Risk Assessment via Cost EstimationKian D Samadian, Paul Chong, Boyu Peng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2010
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agentsMonique Dail, Qing Li, Andrew McDaniel, et al.
Blood|December 18, 2010
Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locusQing Li, Kevin M Haigis, Andrew McDaniel, et al.
British Journal of Haematology|May 29, 2023
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREENeil P Shah, Valentín García-Gutiérrez, Antonio Jiménez-Velasco, et al.
The New England Journal of Medicine|June 16, 2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasMoshe Talpaz, Neil P Shah, Hagop Kantarjian, et al.
Blood|December 7, 2013
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Hagop M Kantarjian, Giuseppe Saglio, et al.
Pageof 21